PATH | VRL
Menu

Reactogenicity, Safety and Immunogenicity of a Protein-Based Pneumococcal Vaccine in Gambian Children Aged 2-4 Years: A Phase II Randomized Study

This article, published in Human Vaccines & Immunotherapeutics, reports the results of a study to assess the safety and immunogenicity of a protein-based pneumococcal vaccine candidate. The authors found the vaccine to be well tolerated and immunogenic in Gambian children. This clinical trial represents the first time that a protein-based pneumococcal vaccine was administered to African children.

Author: Odutola A, Ota MO, Ogundare EO, et al.

Published: 2016

» Visit web page (English)

(Located at www.tandfonline.com)

Citation: Odutola A, Ota MO, Ogundare EO, et al. Reactogenicity, Safety and Immunogenicity of a Protein-Based Pneumococcal Vaccine in Gambian Children Aged 2-4 Years: A Phase II Randomized Study. Human Vaccines & Immunotherapeutics. 2016;12(2):393-402.

Resource types: Peer-reviewed journal

Diseases/vaccines: Pneumococcus

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Africa